viewScancell Holdings PLC

Scancell exploring new frontiers in cancer research


Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology

lab worker

Quick facts: Scancell Holdings PLC

Price: 4.75 GBX

Market: LSE
Market Cap: £22.1 m
  • Developing innovative cancer immunotherapies
  • Four lead products in development
  • Phase II and phase I/II studies in progress or preparation targeting multiple cancer indications

What the company does

AIM-listed Scancell Holdings PLC (LON:SCLP) is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing promise – they are the ImmunoBody and Moditope platforms.

The former has spawned the company’s most advanced cancer drugs, SCIB-1 and SCIB-2. It is also developing MODI-1 and MODI-2 from the Moditope platform.

Scancell Holdings PLC (LON:SCLP)  lead drug, SCIB-1, developed from its ImmunoBody technology, has recently entered a phase II clinical trial in the UK.

The study will initially assess the safety and efficacy of the treatment in 25 people with a metastatic form of skin cancer, melanoma. SCIB-1 will be used in harness with Merck’s checkpoint inhibitor Keytruda.

Scancell remains in discussions with regulators over the minutiae of a parallel clinical assessment in the US.

A £3.9mln injection from the life sciences fund Vulpes will effectively bankroll the latest R&D.

The deficit for the year was £5.6mln as development expenditure grew to £4.15mln.

In September, Scancell signed its first collaboration deal with an unnamed “leading antibody technology company” as it bids to develop an early-stage technology created to directly kill tumour cells.

Inflexion points

The company expects to generate meaningful clinical data in the next two years from all four of its drug candidates (see below).


In recent updates investors have been told CRUK is planning a clinical trial to investigate the safety and efficacy of the SCIB2-nanoparticle complex in patients with solid tumours.

And a planned phase I/II clinical study is of MODI-1 is expected to begin in the second half.

Meanwhile, the company is already signing collaboration deals for its AvidiMab technology, having currently inked a deal with three partners, most recently a US antibody company in January.

The US firm will conduct preclinical studies to evaluate the potential for the anti-TaG mAbs developed by AvidiMab to treat cancer. A similar deal was secured with a Chinese biotech in December.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...



Morning Report: Scancell receives US approval for its SCIB1 skin cancer...

Headlines from the Proactive UK newsroom. Scancell (LON:SCLP) has received IND approval from the US FDA for its SCIB1 skin cancer treatment. the company will now start a US Phase 2 trial in combination with leading drug Keytruda to see if it reduces toxicity compared to other...

on 3/2/20

2 min read